<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

Takeda Pharmaceuticals' Ling Wang Talks Model-based Dose-finding Designs

| |

 

A popular trend in current dose-finding studies moves away from traditional rule-based study designs (e.g. 3+3) and instead uses model-based designs to make dosing decisions during a trial. In this video from Cytel and Sanofi/Genzyme's single day forum on early phase oncology studies, Ling Wang of Takeda Pharmaceuticals gives a talk on single-agent and combination dose-finding designs.

Related Items of Interest

[1] Bayesian Dose Escalation Designs for Late Onset Toxicity

[2] 2 Talks on Early Phase Go/No-GO Decision Making

 

contact iconSubscribe back to top